[{"data":1,"prerenderedAt":174},["ShallowReactive",2],{"drug-exenatide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":36,"contraindications":64,"warnings":74,"renal":82,"monitoring":91,"interactions":92,"review":93,"examples":96,"atc":103,"iran":105,"usApproval":117,"links":123,"populations":140},"exenatide",1,{"fa":7,"en":8},"اگزناتاید","Exenatide","alimentary-metabolism",{"fa":11,"en":12},"آگونیست گیرنده GLP-1","GLP-1 receptor agonist",[14],{"name":15,"market":16},"Byetta","US",[18,19,20,21],"byetta","بایتا","اگزناتید","اکسناتاید",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":31,"refs":32},"pen-250","injection","sc","250 mcg\u002FmL prefilled pen (5 or 10 mcg per dose)",{"amount":29,"unit":30,"perVolumeMl":5},250,"mcg",[16],[33],{"source":34,"section":35},"fda-byetta","3",[37],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":30,"dose":48,"refs":52,"notes":55},"t2dm","type-2-diabetes",{"fa":41,"en":42},"دیابت نوع ۲ — ۵ mcg زیرجلدی دو بار در روز ظرف ۶۰ دقیقه پیش از صبحانه و شام؛ پس از ۱ ماه تا ۱۰ mcg","Type 2 diabetes — 5 mcg SC twice daily within 60 min before morning and evening meals; 10 mcg after 1 month",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":49,"perDoseMax":50,"dosesPerDay":51},5,10,2,[53],{"source":34,"section":54},"2.1",[56],{"text":57,"refs":60},{"fa":58,"en":59},"پس از غذا تزریق نشود. قلم بین بیماران مشترک نشود.","Do not inject after a meal. Never share a pen between patients.",[61,62],{"source":34,"section":54},{"source":34,"section":63},"5.2",[65],{"id":66,"severity":67,"text":68,"refs":71},"ci","block",{"fa":69,"en":70},"حساسیت شدید قبلی به اگزناتاید؛ سابقه ترومبوسیتوپنی ایمنی ناشی از فرآورده‌های اگزناتاید.","Prior severe hypersensitivity to exenatide; history of drug-induced immune-mediated thrombocytopenia from exenatide products.",[72],{"source":34,"section":73},"4",[75],{"text":76,"refs":79},{"fa":77,"en":78},"پانکراتیت حاد؛ هیپوگلیسمی با سولفونیل‌اوره یا انسولین؛ آسیب حاد کلیه با کاهش حجم؛ عوارض شدید گوارشی؛ ترومبوسیتوپنی؛ بیماری کیسه صفرا؛ آسپیراسیون ریوی حین بیهوشی.","Acute pancreatitis; hypoglycaemia with sulfonylureas or insulin; acute kidney injury from volume depletion; severe GI reactions; thrombocytopenia; gallbladder disease; pulmonary aspiration during anaesthesia.",[80],{"source":34,"section":81},"5",[83],{"egfrBelow":84,"severity":67,"text":85,"refs":88},30,{"fa":86,"en":87},"ClCr زیر ۳۰ یا ESRD: توصیه نمی‌شود.","CrCl \u003C30 or ESRD: not recommended.",[89],{"source":34,"section":90},"8.6",[],[],{"status":94,"reviewer":95,"date":95},"unverified",null,[97],{"regimen":38,"formulation":24,"input":98,"expect":101},{"ageYears":99,"weightKg":100},55,90,{"perDose":49,"mlPerDose":102,"upperPerDose":50},0.02,[104],"A10BJ01",{"status":106,"forms":107,"refs":112},"registered",[108],{"code":109,"en":110,"fa":111},"51329","EXENATIDE INJECTION, SUSPENSION, EXTENDED RELEASE PARENTERAL 2 mg","فرآورده تزریقی اکسناتاید ۲ میلی‌گرم",[113],{"source":114,"section":115,"url":116},"darooyab-generic","G-4914\u002FExenatide","https:\u002F\u002Fwww.darooyab.ir\u002FG-4914\u002FExenatide",{"kind":118,"refs":119,"id":122},"NDA",[120],{"source":34,"section":121},"SPL approval \u002F marketing category","NDA021773",[124,127,131,135,138],{"kind":125,"url":126,"label":122},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021773",{"kind":128,"url":129,"label":130},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f","FDA Byetta",{"kind":132,"url":133,"label":134},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa605034.html","Exenatide Injection",{"kind":136,"url":137,"label":104},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BJ01",{"kind":139,"url":116,"label":8},"darooyab",{"pregnancy":141,"lactation":150,"pediatric":158,"geriatric":166},{"level":142,"text":143,"quote":146,"refs":147},"caution",{"fa":144,"en":145},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited data with BYETTA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage.",[148],{"source":34,"section":149},"8.1",{"level":142,"text":151,"quote":154,"refs":155},{"fa":152,"en":153},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of BYETTA, in human milk, the effects of BYETTA on the breastfed infant, or the effects of BYETTA on milk production.",[156],{"source":34,"section":157},"8.2",{"level":142,"text":159,"quote":162,"refs":163},{"fa":160,"en":161},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of BYETTA have not been established in pediatric patients.",[164],{"source":34,"section":165},"8.4",{"level":142,"text":167,"quote":170,"refs":171},{"fa":168,"en":169},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function.",[172],{"source":34,"section":173},"8.5",1792191543504]